[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"mci\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:mci":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,20,0,[8,56,92,126,152,182,208,235,262,291,311,334,359,391,417,446,469,491,512,546],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":31,"overallStatus":44,"whyStopped":4,"lastUpdateSubmitDate":45,"lastUpdatePostDateStruct":46,"startDateStruct":49,"completionDateStruct":50,"leadSponsor":52,"locationsCount":55},"100621109","telehealth-adapted-compensatory-training-and-intervention-for-cognition-100621109",false,"NCT07366346","Telehealth-Adapted Compensatory Training and Intervention for Cognition","Telehealth-Adapted Compensatory Training and Intervention for Cognition for People With Mild Cognitive Impairment","TACTIC","Inclusion Criteria:\n\n* 65 years of age or older, less than 85 years\n* Have the ability to speak and understand English\n* Time and willingness to commit to the completion of this study\n* Availability of a study partner (typically a relative, spouse, offspring, or roommate) for initial and post-intervention testing\n* A global Clinical Dementia Rating scale (CDR) score of 0.5 and cognitive performance of \\\u003C26 on the Montreal Cognitive Assessment (MoCA) or \\\u003C19 on the MoCA-BLIND for categorization of MCI, as determined in the screening appointment.\n\nExclusion Criteria:\n\n* Self-reported diagnosis of dementia or functional impairment that requires assistance\n* Recent changes in medications for memory (i.e., prescribed or changed medications for memory within 30 days)\n* Major psychiatric illness (schizophrenia, current substance dependence, or undertreated depression or anxiety), or 15-item Geriatric Depression Scale (GDS-15) score of eight or higher\n* Hearing, vision, or motor deficits that would interfere with standardized cognitive assessment or participation in study interventions: e.g., inability to hear through headphones (with or without hearing aids). If vision is corrected with lenses to appropriate levels, then participant will be eligible\n* No access to reliable, stable internet, OR\n* Current participation in another cognitive training program or treatment study.","ALL","65 Years","84 Years",{"count":21,"type":22},100,"ESTIMATED","INTERVENTIONAL",[25],"NA","The goal of this clinical trial is to develop a five-week virtual cognitive training intervention for people with Mild Cognitive Impairment (MCI) based off an existing eight-week intervention. The main question it aims to answer is:\n\n• Is five weeks of training as good as eight weeks in improving cognition, quality of life, daily functioning, and mood, and in reducing caregiver burden? Researchers will compare five weeks of cognitive training to eight weeks of training to see if the shorter version is as effective as the full training.\n\nParticipants will complete all activities virtually:\n\n* Complete a screening visit with a study partner (typically a family member, roommate, or close friend) to determine eligibility to participate in the study\n* Complete some tests of memory and thinking and some questionnaires\n* Attend weekly two-hour group cognitive training sessions with a trained group leader, for five or eight weeks\n* Redo the questionnaires and tests of memory and thinking immediately after completing the training, and three months after completing the training",[28,29,30],"MCI","Mild Cognitive Impairment","Mild Cognitive Impairment (MCI)",[32,33,34,35,36,37,38,39,40,41,42,43],"cognitive training","compensatory cognitive training","mild cognitive impairment","cognitive decline","cognitive intervention","cognitive strategies","group intervention","everyday functioning","cognition","brain health","dementia prevention","dementia","RECRUITING","2026-05-29",{"date":47,"type":48},"2026-06-03","ACTUAL",{"date":45,"type":48},{"date":51,"type":22},"2027-08",{"name":53,"class":54},"University of Florida","OTHER",1,{"id":57,"slug":58,"hasResults":11,"nctId":59,"briefTitle":60,"officialTitle":61,"acronym":62,"eligibilityCriteria":63,"healthyVolunteers":64,"sex":17,"minAge":65,"maxAge":4,"enrollmentInfo":66,"targetDuration":4,"studyType":23,"phases":68,"briefSummary":69,"conditions":70,"keywords":72,"overallStatus":83,"whyStopped":4,"lastUpdateSubmitDate":84,"lastUpdatePostDateStruct":85,"startDateStruct":86,"completionDateStruct":88,"leadSponsor":90,"locationsCount":55},"100637080","tailored-brain-health-insights-through-nurturing-knowledge-based-change---stakeholder-driven-human-centered-ai-powered-refinement-for-prevention-100637080","NCT07612800","Tailored Brain Health Insights Through Nurturing Knowledge-based Change - Stakeholder-driven, Human-centered, AI-powered Refinement for Prevention","Tailored Brain Health Insights Through Nurturing Knowledge-based Change - Stakeholder-driven, Human-centered, AI-powered Refinement for Prevention (THINK-SHARP)","THINK-SHARP","Inclusion Criteria:\n\n* Community-dwelling adults\n* Aged 40 years and above at time of recruitment\n* Able to use a smartphone and smartphone applications\n* Able to provide written informed consent\n\nExclusion Criteria:\n\n* Been diagnosed wotj dementia, neurocognitive disorder or any major psychiatric illness\n* Have severe sensory or physical disability precluding usage of the application\n* Terminal illness or expected survival of less than 12 months at point of recruitment",true,"40 Years",{"count":67,"type":22},350,[25],"The goal of this clinical trial is to evaluate whether an AI-powered digital brain health coaching intervention can improve modifiable brain health risk factors in community-dwelling adults aged 40 and above in Singapore.\n\nThe main question it aims to answer is: does the use of BLAZE, an AI-powered digital brain health coaching intervention, lead to a greater improvement in Brain Care Score (BCS) compared to usual care at 6 months?\n\nResearchers will compare participants receiving BLAZE to those receiving usual care (waitlist control) to see if BLAZE leads to greater improvements in brain health risk factors, behavioural outcomes, quality of life, and cost-effectiveness.\n\nParticipants will:\n\n* Be randomly assigned to either receive BLAZE immediately for 12 months or be placed on a waitlist receiving usual care for the first 6 months before receiving BLAZE for a further 6 months\n* Complete a series of assessments at baseline, 6 months, and 12 months including the Brain Care Score, physical function tests, cognitive assessments, quality of life measures, and lifestyle behaviour questionnaires\n* If assigned to the intervention group, interact with BLAZE via a WhatsApp-based platform that delivers personalised brain health recommendations, behavioural nudges, educational content, and goal-setting support based on their individual Brain Care Score profile",[28,71],"Dementia",[73,74,75,76,77,78,79,80,81,82],"COM-B","artificial intelligence","digital health intervention","mHealth","conversational agent","large language model","Whatsapp-based intervention","Just-in-time adaptive intervention (JITAI)","brain health coaching","behavioural nudging","NOT_YET_RECRUITING","2026-05-21",{"date":45,"type":48},{"date":87,"type":22},"2026-09-01",{"date":89,"type":22},"2029-12-31",{"name":91,"class":54},"Alexandra Hospital",{"id":93,"slug":94,"hasResults":11,"nctId":95,"briefTitle":96,"officialTitle":97,"acronym":4,"eligibilityCriteria":98,"healthyVolunteers":64,"sex":17,"minAge":99,"maxAge":100,"enrollmentInfo":101,"targetDuration":4,"studyType":23,"phases":103,"briefSummary":105,"conditions":106,"keywords":108,"overallStatus":44,"whyStopped":4,"lastUpdateSubmitDate":116,"lastUpdatePostDateStruct":117,"startDateStruct":119,"completionDateStruct":121,"leadSponsor":123,"locationsCount":55},"100637171","phase-1-a-phase-i-study-of-18fflortaucipir-pet-imaging-in-chinese-subjects-safety-pharmacokinetics-biodistribution-radiation-dosimetry-and-preliminary-diagnostic-efficacy-100637171","NCT07580703","A Phase I Study of [18F]Flortaucipir PET Imaging in Chinese Subjects: Safety, Pharmacokinetics, Biodistribution, Radiation Dosimetry, and Preliminary Diagnostic Efficacy","A Non Randomized, Open-Label Phase I Study to Evaluate the Safety and Tolerability, Pharmacokinetics, Biodistribution and Radiation Dosimetry, and Preliminary Diagnostic Efficacy of [18F]Flortaucipir Injection PET Imaging in Chinese Subjects","Inclusion Criteria:\n\n* Signed informed consent form (ICF).\n* Male or female aged 50-85 years.\n* Education level sufficient to cooperate with neuropsychological testing and obtain reliable results.\n* Meet the following criteria related to cognitive impairment:\n\n  1. CN: No history of cognitive impairment, Aβ-PET negative, MRI without clinically significant neurodegenerative changes.\n  2. MCI: Meet core criteria for AD-related MCI, Aβ-PET positive, MRI showing neurodegenerative changes.\n  3. AD: Meet core criteria for probable AD dementia, Aβ-PET positive, MRI showing neurodegenerative changes.\n* Fertile individuals: No plan for reproduction, sperm\u002Fegg donation within 6 months after signing ICF and until 6 months after study drug administration; and agreement to use highly effective contraception (including partner).\n\nExclusion Criteria:\n\n* Pregnant (positive pregnancy test at screening or before administration) or breastfeeding women.\n* Major surgery within 1 month prior to screening, or planned surgery during the study period.\n* Known allergy to radioactive radiation, alcohol, \\[18F\\]Flortaucipir injection, or its excipients, or other severe allergic reactions.\n* Cognitive impairment due to causes other than AD.\n* Clinically significant infarction or probable multi-infarct dementia.\n* Current clinically significant psychiatric illness (e.g., major depression, schizophrenia).\n* History of epilepsy or seizures (except febrile seizures in childhood).\n* Inability to tolerate PET\u002FMRI or presence of contraindications to PET\u002FMRI.\n* Other neurodegenerative diseases or dementias other than AD dementia.\n* Any other condition that, in the investigator's opinion, makes the subject unsuitable for the study.","50 Years","85 Years",{"count":102,"type":22},18,[104],"PHASE1","This is a non randomized, open-label Phase I study in Chinese participants. The goal of this clinical trial is to evaluate the safety and tolerability of a radioactive imaging agent called \\[18F\\]Flortaucipir Injection, which is used during a PET scan. The study will also measure how the agent moves through the body (pharmacokinetics), where it goes (biodistribution), the amount of radiation exposure (radiation dosimetry), and how well it may help detect signs of disease (preliminary diagnostic efficacy).",[107,28],"AD - Alzheimer's Disease",[109,110,111,112,113,114,115,28],"tau-PET","[18F]Flortaucipir","Phase I","ELI-101","ELI-101-001","AD","Alzheimer's disease","2026-05-11",{"date":118,"type":48},"2026-05-14",{"date":120,"type":48},"2026-04-23",{"date":122,"type":22},"2027-03-31",{"name":124,"class":125},"Eli Radiopharma","INDUSTRY",{"id":127,"slug":128,"hasResults":11,"nctId":129,"briefTitle":130,"officialTitle":130,"acronym":4,"eligibilityCriteria":131,"healthyVolunteers":64,"sex":17,"minAge":132,"maxAge":100,"enrollmentInfo":133,"targetDuration":4,"studyType":23,"phases":135,"briefSummary":136,"conditions":137,"keywords":138,"overallStatus":83,"whyStopped":4,"lastUpdateSubmitDate":143,"lastUpdatePostDateStruct":144,"startDateStruct":146,"completionDateStruct":148,"leadSponsor":150,"locationsCount":55},"100632323","personalized-closed-loop-brain-stimulation-for-patients-with-mild-cognitive-impairment-100632323","NCT07512193","Personalized Closed-Loop Brain Stimulation for Patients With Mild Cognitive Impairment","Inclusion Criteria:\n\n* Must be between 45-85 years of age.\n* Must be proficient in English.\n* Must have a minimum of high-school education.\n* Must be diagnosed with 'probable Alzheimer's Disease (AD)' in specialized diagnostic centers with neuropsychological (e.g., RAVLT) and AD biomarkers according to 2011 guidelines.\n* The investigators will also perform extensive testing in the investigators' test battery including the Mnemonic Similarity Test (MST) that discriminates and measures the most salient hippocampal deficit-pattern separation (PS).\n\nExclusion Criteria:\n\n* People with previous neurological disease including vascular dementia (e.g., stroke, developmental dyslexia, dysgraphia or attentional deficit).\n* People with hearing loss (\\> 25 decibel, using audiometric hearing screen).\n* People with uncorrected visual acuity loss.\n* People with advanced dementia or severe language impairments (MMSE \\\u003C15, or Montreal Cognitive Assessment \\\u003C10, or language Frontotemporal Dementia-specific Clinical Dementia Rating (FTD-CDR) =3).\n* People with pre-existing psychiatric disorders such as behavioral disturbances, severe depression, or schizophrenia that do not allow these people to comply or follow the study schedule and requirements such as repeated evaluation and therapy.","45 Years",{"count":134,"type":22},10,[25],"This research study investigates the feasibility and efficacy of a personalized, closed-loop electroencephalogram-transcranial electrical stimulation (EEG-tES) intervention for individuals with mild cognitive impairment (MCI), addressing the inconsistent results of generic brain stimulation protocols. By integrating artificial intelligence (AI)-derived insights with real-time data, the study aims to customize transcranial electrical stimulation (tES) parameters, including electrode placement, intensity, and frequency to target the specific brain regions responsible for abnormal signaling in each participant. Over the intervention period paired with computerized cognitive training, the project will evaluate improvements in learning, memory, and functional connectivity, while simultaneously identifying clinical and physiological predictors to determine the viability of transitioning this low-cost, non-invasive technology into a remotely supervised, home-based therapy setting. The study duration will be a total of 6-8 weeks.",[28],[28,139,140,141,142],"EEG","tES","Personalized treatment","Closed-loop","2026-05-06",{"date":145,"type":48},"2026-05-08",{"date":147,"type":22},"2026-06",{"date":149,"type":22},"2026-08",{"name":151,"class":54},"Johns Hopkins University",{"id":153,"slug":154,"hasResults":11,"nctId":155,"briefTitle":156,"officialTitle":156,"acronym":157,"eligibilityCriteria":158,"healthyVolunteers":11,"sex":17,"minAge":159,"maxAge":160,"enrollmentInfo":161,"targetDuration":4,"studyType":23,"phases":162,"briefSummary":163,"conditions":164,"keywords":169,"overallStatus":83,"whyStopped":4,"lastUpdateSubmitDate":173,"lastUpdatePostDateStruct":174,"startDateStruct":176,"completionDateStruct":178,"leadSponsor":180,"locationsCount":55},"100625073","ketogenic-diet-to-reduce-osteoarthritis-pain-in-mci-100625073","NCT07417891","Ketogenic Diet to Reduce Osteoarthritis Pain in MCI","KDROP-MCI","Inclusion Criteria:\n\n* English speaking\n* Diagnosis of major joint osteoarthritis\n* Diagnosis of mild cognitive impairment\n\nExclusion Criteria:\n\n* Diabetes that requires insulin\n* Cancer requiring chemo- or radiation therapy in the last 2 years\n* Cardiac event within 1 year\n* Recent history of renal stones\n* Diagnosis of fibromyalgia\n* Already following a ketogenic diet\n* Following a dietary pattern that does not allow for a ketogenic approach\n* Unable to control one's diet","55 Years","75 Years",{"count":134,"type":22},[25],"Osteoarthritis and mild cognitive impairment are common conditions that share underlying biological processes related to metabolism and inflammation. This study will examine whether a well-formulated ketogenic diet influences pain, physical function, and cognitive outcomes in adults with osteoarthritis and mild cognitive impairment. Participants will follow a supervised ketogenic dietary intervention, with assessments conducted before and after the intervention to evaluate changes in symptoms and related biological markers. The goal of this study is to better understand shared mechanisms between joint pain and cognitive health and to explore whether a ketogenic dietary approach may support symptom management in these populations.",[165,166,167,168,29,28,30,71],"Osteoarthritis (OA) of the Hip","Osteoarthritis (OA) of the Knee","Osteoarthritis (OA) of the Shoulder","Osteoarthritis",[170,171,172,34],"ketogenic diet","chronic pain","osteoarthritis","2026-04-30",{"date":175,"type":48},"2026-05-04",{"date":177,"type":22},"2026-06-01",{"date":179,"type":22},"2027-06-01",{"name":181,"class":54},"University of Kansas Medical Center",{"id":183,"slug":184,"hasResults":11,"nctId":185,"briefTitle":186,"officialTitle":187,"acronym":4,"eligibilityCriteria":188,"healthyVolunteers":64,"sex":17,"minAge":189,"maxAge":190,"enrollmentInfo":191,"targetDuration":4,"studyType":23,"phases":193,"briefSummary":195,"conditions":196,"keywords":4,"overallStatus":44,"whyStopped":4,"lastUpdateSubmitDate":199,"lastUpdatePostDateStruct":200,"startDateStruct":202,"completionDateStruct":204,"leadSponsor":206,"locationsCount":55},"100602988","phase-1-face-phase-ii-a-stage-ii-trial-100602988","NCT07130669","FACE Phase II (a Stage II Trial)","A Facial Expression-based Personalization Engine (FPE) for Monitoring and Modulating Real-time Effective Engagement in Cognitive Training in Older Adults at Risk for AD\u002FADRD (CogT FACE Study Phase II)","Inclusion Criteria:\n\n1. English speaking\n2. Aged 60-89\n3. Living in a home, or independent- or assisted-living facility\n4. Adequate visual and hearing acuity\n5. Anti-depressants, antipsychotics, and\u002For anxiolytics have been stable for at least 7 days\n6. Memory medications have been stable for at least 3 months\n7. Absence of neurological\u002Fvascular disorder (For neurological disorders with minor symptoms check with PI on case-by-case basis)\n\nExclusion Criteria:\n\n1. be enrolled in another intervention study aimed at improving cognition\n2. live in nursing home\n3. diagnosed with Multiple Sclerosis, TBI, chronic heart failure, Parkinson's disease, dementia","60 Years","89 Years",{"count":192,"type":22},80,[104,194],"PHASE2","How to ensure adherence to computerized cognitive training in unsupervised circumstances (e.g., at-home, self-administered) in older adults at risk for Alzheimer's disease (AD) or AD related dementia (AD\u002FADRD) is understudied. The objective of the R33 study is to test a novel facial expression-based personalization engine (FPE) for monitoring and modulating real-time effective engagement, with an ultimate goal of enhancing long-term adherence in unsupervised cognitive training in older adults at risk for AD\u002FADRD. Here, Effective engagement is defined as the extent to which someone is actively engaged and performing with significant attention and enjoyment while training, addressing a balance between adherence and cognitive gains\u002Fplasticity from the training. Based on previous work, the hypotheses include that (1) mental fatigue revealed in facial expressions will reflect a trainee's degree of effective engagement, which can be modified by modulating task novelty; (2) the proposed FPE will ensure the effective engagement in cognitive training by monitoring trainee facial expressions and modulating training in response, promoting the trainee's long-term adherence to the training and cognitive plasticity. A Stage II intervention efficacy study will be conducted to compare effective engagement and adherence in unsupervised cognitive training between training programs with vs. without FPE in older adults at risk for AD\u002FADRD. The proposed FPE may assist in monitoring and improving effective engagement and adherence in older adults with unsupervised cognitive training. In the current application, FPE in a cognitive training program called speed of processing training will be tested. However, such FPE may be embedded to any computerized cognitive training in future studies to help address adherence related issues.",[28,197,198],"Subjective Cognitive Decline (SCD)","Mild Behavioral Impairment","2026-04-21",{"date":201,"type":48},"2026-04-24",{"date":203,"type":48},"2025-10-31",{"date":205,"type":22},"2028-08-31",{"name":207,"class":54},"Stanford University",{"id":209,"slug":210,"hasResults":11,"nctId":211,"briefTitle":212,"officialTitle":213,"acronym":4,"eligibilityCriteria":214,"healthyVolunteers":64,"sex":17,"minAge":159,"maxAge":215,"enrollmentInfo":216,"targetDuration":4,"studyType":23,"phases":218,"briefSummary":219,"conditions":220,"keywords":222,"overallStatus":83,"whyStopped":4,"lastUpdateSubmitDate":226,"lastUpdatePostDateStruct":227,"startDateStruct":229,"completionDateStruct":231,"leadSponsor":233,"locationsCount":55},"100605289","cognitive-motor-training-for-adadrd-prevention-100605289","NCT07160582","Cognitive-Motor Training for AD\u002FADRD Prevention","Innovative Cognitive-Motor Training for Prevention of AD\u002FADRD","Inclusion Criteria:\n\n1. Age: 55-90 years.\n2. No recent major surgery, bone fracture, or hospitalization (\\\u003C 3 months).\n3. Not on any sedative drugs.\n4. Can understand and communicate in English.\n5. Can walk without an assistive device for at least 1 block to ensure independent functioning.\n6. Identification of Mild Cognitive Impairment (MCI) based on Jak\u002FBondi criteria\n7. Visual acuity greater than or equal to 20\u002F40 with or without corrective lenses to ensure intact vision.\n\nExclusion Criteria:\n\n1. Participants will not proceed with the study if any of the following occurs at baseline measurement: 1) Heart Rate \\>85% of age-predicted maximal heart rate (HRmax) (HRmax = 220 - age), 2) systolic blood pressure (SBP) \\> 160 mmHg and\u002For diastolic blood pressure (DBP) \\> 110 mmHg during resting.\n2. Unable to stand for 5 minutes without an assistive device and walk for 10 m without an assistive device\n3. Complaints of shortness of breath, or uncontrolled pain (more than 3 out of 10 on Visual Analogue Scale), or if pulse oxygen drops less than 92% on the six-minute walk test (for endurance) to ensure that the participant can effectively participate without discomfort or injury during testing and training.\n4. Exhibits difficulty understanding the study information.\n5. Self-reported history or presence of any neurological, musculoskeletal, cardiorespiratory, or systemic disorders that significantly impact mobility or the ability to walk independently (without an assistive device).\n6. Self-reported disability (with or without an assistive device) to ensure independent functioning.\n7. Uncontrolled (not under any medications) hypertension to avoid cardiovascular complications during testing\u002Ftraining.\n8. Weight \\>220 lbs (harness weight threshold).","90 Years",{"count":217,"type":22},46,[25],"Alzheimer's disease and related dementias (AD\u002FADRD) greatly affect memory and daily activities in older adults. Mild Cognitive Impairment (MCI) is an early stage of dementia, affecting about 17% of older adults. People with MCI often show problems with gait and balance, which doubles their risk of falling compared to cognitively healthy peers. Falls can cause injuries, increase sedentary behavior, and reduce physical activity. This decline in activity can also speed up the progression from MCI to dementia. Exercise can help older adults make healthy lifestyle changes; however, most of the existing exercise programs focus mainly on physical movement rather than cognitive function. Therefore, the investigators developed a new program that uses computer vision and a cloud-based system to provide more scalable, engaging, and personalized cognitive-motor training for OAwMCI. The purpose of this study is to investigate the short- and long-term effects of a novel CogXergaming training (CXT) paradigm for improving the cognitive-motor function, physical activity, falls efficacy, and quality of life.",[28,221],"Aging",[223,224,225],"CogXergaming","Cognitive-motor interference","Dual-task","2026-03-19",{"date":228,"type":48},"2026-03-24",{"date":230,"type":22},"2026-05-01",{"date":232,"type":22},"2027-09-01",{"name":234,"class":54},"University of Illinois at Chicago",{"id":236,"slug":237,"hasResults":11,"nctId":238,"briefTitle":239,"officialTitle":240,"acronym":241,"eligibilityCriteria":242,"healthyVolunteers":64,"sex":17,"minAge":189,"maxAge":100,"enrollmentInfo":243,"targetDuration":4,"studyType":23,"phases":245,"briefSummary":246,"conditions":247,"keywords":248,"overallStatus":44,"whyStopped":4,"lastUpdateSubmitDate":254,"lastUpdatePostDateStruct":255,"startDateStruct":257,"completionDateStruct":259,"leadSponsor":260,"locationsCount":55},"100564807","studying-the-effects-of-digital-interventions-on-cognition-wellbeing-stress-and-sleep-in-older-adults-100564807","NCT06633978","Studying the Effects of Digital Interventions on Cognition, Wellbeing, Stress, and Sleep in Older Adults","A Pilot Study of the Impact of Personalized Digital Meditation on Improving Sleep and Reducing Stress in MCI","MediDream","* comfortably ambulatory healthy physical condition\n* normal or corrected to normal visual\n* auditory acuity\n* fluency in spoken English\n* Between 60-85 years old\n* No neurological or psychiatric disorders\n* No substance abuse\n* Not taking anti-depressants\n* Not taking anti-anxiety medication\n* No history of seizures\n* No color blindness\n* No glaucoma\n* No macular degeneration\n* No amblyopia (lazy eye)\n* No strabismus (cross eyed)\n* Aneurysm clip(s)\n* No Cardiac pacemaker\n* No Implanted cardioverter defibrillator (ICD)\n* No Electronic implant or device\n* No Magnetically-activated implant or device\n* No Neurostimulation system\n* No Spinal cord stimulator\n* No Internal electrodes or wires\n* No Bone growth\u002Fbone fusion stimulator\n* No Cochlear, otologic, or other ear implant\n* No Insulin or other infusion pump\n* No Implanted drug infusion device\n* No type of prosthesis (eye, penile, etc.)\n* No Heart valve prosthesis\n* No Eyelid spring or wire\n* No Artificial or prosthetic limb\n* No Metallic stent, filter, or coil\n* No Shunt (spinal or intraventricular)\n* No Vascular access port and\u002For catheter\n* No Radiation seeds or implants\n* No Swan-Ganz or thermodilution catheter\n* No Medication patch (Nicotine, Nitroglycerine)\n* No metallic fragment or metallic foreign body in\u002Fon the body that can not be removed\n* No Wire mesh implant\n* No Tissue expander (e.g., breast)\n* No Surgical staples, clips, or metallic sutures\n* No Joint replacement (hip, knee, etc.)\n* No Bone\u002Fjoint pin, screw, nail, wire, plate, etc.\n* No IUD, diaphragm, or pessary\n* No Dentures or partial plates that can not be removed\n* No Tattoo or permanent makeup\n* No Body piercing jewelry\n* No Claustrophobia",{"count":244,"type":22},90,[25],"The goal of this proposed research is to collect pilot data to test the hypothesis that treatment with a novel form of closed-loop digital meditation (MediTrain) will lead to a greater magnitude of gains in cognitive abilities in patients with mild cognitive impairment (MCI), compared to OA without cognitive impairment, and will lead to improvements in quantitative measures of sleep.",[28,221],[249,250,251,252,40,253],"meditation","sleep","stress","attention","memory","2026-02-20",{"date":256,"type":48},"2026-02-24",{"date":258,"type":48},"2024-09-10",{"date":149,"type":22},{"name":261,"class":54},"University of California, San Francisco",{"id":263,"slug":264,"hasResults":11,"nctId":265,"briefTitle":266,"officialTitle":267,"acronym":4,"eligibilityCriteria":268,"healthyVolunteers":64,"sex":17,"minAge":189,"maxAge":269,"enrollmentInfo":270,"targetDuration":4,"studyType":23,"phases":272,"briefSummary":273,"conditions":274,"keywords":276,"overallStatus":44,"whyStopped":4,"lastUpdateSubmitDate":254,"lastUpdatePostDateStruct":285,"startDateStruct":286,"completionDateStruct":288,"leadSponsor":290,"locationsCount":55},"100546632","enhancing-attention-and-wellbeing-using-digital-therapeutics-100546632","NCT06397469","Enhancing Attention and Wellbeing Using Digital Therapeutics","Optimizing a Closed-loop Digital Meditation Intervention for Remediating Cognitive Decline and Reducing Stress in Older Adults","Inclusion Criteria:\n\n* 60+ years old (adult)\n* English language fluency\n* owning a smartphone or tablet\n\nExclusion Criteria:\n\n* Under 60 years old (minor)","99 Years",{"count":271,"type":22},4000,[25],"The goals of the proposed research are to first determine the minimal and\u002For optimal dose of a digital intervention required for cognitive enhancement, and then to examine the impact of several potential moderators of treatment effects (i.e., cognitive decline, AD polygenic hazard score, cardiovascular risk, and race\u002Fethnicity). This knowledge gained from his high-impact study with transform the field of cognitive interventions, paving the way for a precision medicine model for cognitive enhancing interventions that improve quality of life for older adults and individuals with cognitive deficits at risk of developing dementia.",[221,28,275],"Cognitive Decline",[277,252,40,43,278,279,280,281,282,283,284],"healthy aging","intervention","digital","behavioral","prevention","decline","stress reduction","Quality of life",{"date":256,"type":48},{"date":287,"type":48},"2024-04-01",{"date":289,"type":22},"2029-06",{"name":261,"class":54},{"id":292,"slug":293,"hasResults":11,"nctId":294,"briefTitle":295,"officialTitle":295,"acronym":28,"eligibilityCriteria":296,"healthyVolunteers":11,"sex":17,"minAge":159,"maxAge":4,"enrollmentInfo":297,"targetDuration":4,"studyType":299,"phases":4,"briefSummary":300,"conditions":301,"keywords":4,"overallStatus":44,"whyStopped":4,"lastUpdateSubmitDate":302,"lastUpdatePostDateStruct":303,"startDateStruct":305,"completionDateStruct":307,"leadSponsor":309,"locationsCount":55},"100611760","the-effects-of-some-antihyperglycemic-drugs-on-cognitive-function-and-risk-of-depression-of-diabetic-patients-100611760","NCT07244770","The Effects of Some Antihyperglycemic Drugs on Cognitive Function and Risk of Depression of Diabetic Patients","Inclusion Criteria:\n\n\\-\n\nThe study participants should meet the following inclusion criteria:\n\n1. T2DM adult subjects (\\>55 years old) will be eligible to participate.\n2. Patients should be taking SGLT2Is+metformin or DDP4Is + metformin for at least 1 year to be eligible.\n\nExclusion Criteria:\n\n1- Those with type1 diabetes or ketoacidosis, insulin therapy, end organ failure as chronic renal failure, liver, and heart failure, previous history of pancreatitis, history of Alzheimer's disease or any brain insult, and finally pregnant or lactating females will be excluded from the study.",{"count":298,"type":22},300,"OBSERVATIONAL","The study aims to investigate the effects of DPP-4 Is+ metformin versus SGLT2 Is + metformin on the risk of cognitive decline and depression in patients with T2DM.",[28],"2026-01-28",{"date":304,"type":48},"2026-01-30",{"date":306,"type":48},"2025-01-01",{"date":308,"type":22},"2026-12-30",{"name":310,"class":54},"Beni-Suef University",{"id":312,"slug":313,"hasResults":11,"nctId":314,"briefTitle":315,"officialTitle":315,"acronym":316,"eligibilityCriteria":317,"healthyVolunteers":64,"sex":17,"minAge":159,"maxAge":318,"enrollmentInfo":319,"targetDuration":320,"studyType":299,"phases":4,"briefSummary":321,"conditions":322,"keywords":4,"overallStatus":44,"whyStopped":4,"lastUpdateSubmitDate":326,"lastUpdatePostDateStruct":327,"startDateStruct":329,"completionDateStruct":331,"leadSponsor":332,"locationsCount":55},"100613916","neurocognitive-assessment-platform-4-alzheimer-100613916","NCT07272811","Neurocognitive Assessment Platform 4 Alzheimer","NAP4A2020","Inclusion criteria common to both experimental groups:\n\n* Signature of informed consent\n* Age between 55 and 80 years\n* Absence of functional impact on daily living activities or minimal impact on instrumental activities\n\nSpecfic inclusion criteria for Healthy Controls recruitment:\n\n* Normal global cognitive efficiency (Mini Mental State Examination scores of 28 or higher)\n* Absence of specific cognitive deficits (memory and other cognitive domains) that are abnormal for age, sex, and education level (1.5 standard deviations below the mean for age- and education-matched controls), as assessed by objective, standardized cognitive tests.\n\nSpecific inclusion criteria for aMCI recruitment:\n\n* Cognitive difficulties reported by the individual, their family member, or their primary care physician\n* Normal global cognitive efficiency (Mini Mental State Examination score within 0.5 standard deviations of the average for age- and education-matched control subjects).\n* Specific cognitive deficits related to memory or multi-domain cognitive impairments (involving memory and other cognitive domains) that are atypical for the individual's age (1.5 standard deviations below the average for age- and education-matched controls), as determined by objective, standardized cognitive tests.\n\nExclusion Criteria:\n\n* Rejection of informed consent\n* Important sensory deficits (e.g., hearing loss or hypovisus)\n* Current or previous history of psychiatric illness\n* Current or previous degenerative pathology of the central nervous system (CNS)\n* Presence of systemic diseases in anamnesis\n* Presence of cerebrovascular events in anamnesis\n* Use of alcohol or psychotropic substances in anamnesis","80 Years",{"count":21,"type":22},"12 Months","The aging population in Europe is leading to an increase in neurodegenerative diseases, such as Alzheimer's disease (AD), which is expected to affect 152 million people worldwide by 2050. In Italy, there are approximately 1.2 million cases of dementia, with 600,000 attributed to AD. Given the limited effectiveness of current pharmacological treatments, there is a growing need for early, non-pharmacological interventions to slow disease progression and improve the quality of life for patients and caregivers.\n\nThe Neurocognitive Assessment Platform 4 Alzheimer (NAP4A) study aims to create a digital platform for the early detection of amnestic mild cognitive impairment (MCIa), considered an intermediate stage between normal aging and dementia. The platform uses non-invasive biometric tools, including EEG, blood flow sensors, and eye-tracking devices, to collect neurophysiological and behavioral data.\n\nThe study will involve 100 participants aged 55 to 80, divided into two groups: one with individuals diagnosed with MCIa and a control group of healthy participants. Over 12 months, regular assessments will be conducted to identify markers that predict the progression from MCIa to AD. The goal is to develop advanced diagnostic tools that support early and targeted interventions.",[28,323,324,325],"MCI Conversion to Dementia","AMCI - Amnestic Mild Cognitive Impairment","Alzheimer Disease","2026-01-20",{"date":328,"type":48},"2026-01-22",{"date":330,"type":48},"2021-12-15",{"date":147,"type":22},{"name":333,"class":54},"IRCCS San Raffaele",{"id":335,"slug":336,"hasResults":11,"nctId":337,"briefTitle":338,"officialTitle":338,"acronym":4,"eligibilityCriteria":339,"healthyVolunteers":64,"sex":17,"minAge":159,"maxAge":100,"enrollmentInfo":340,"targetDuration":342,"studyType":299,"phases":4,"briefSummary":343,"conditions":344,"keywords":345,"overallStatus":83,"whyStopped":4,"lastUpdateSubmitDate":351,"lastUpdatePostDateStruct":352,"startDateStruct":354,"completionDateStruct":356,"leadSponsor":357,"locationsCount":55},"100615785","validation-of-the-montreal-cognitive-assessment-moca-version-8x-and-moca-mis-in-greece-100615785","NCT07297121","Validation of the Montreal Cognitive Assessment (MoCA) Version 8.x and MoCA-MIS in Greece.","Inclusion Criteria:\n\n* Participants between the ages of 55-85\n* Fluent in Greek to avoid misunderstandings during the assessment\n* Participants must be able to provide informed consent\n\nExclusion Criteria:\n\n* History of severe psychiatric or neurological disorders apart from MCI\u002Fdementia\n* Patients having acute medical illnesses\n* Patients having severe hearing and\u002For visual impairments",{"count":341,"type":22},250,"4 Weeks","Objective: The purpose of this study is to assess the psychometric qualities of the Montreal Cognitive Assessment (MoCA) version 8.x in Greek, including the MoCA-MIS. We intend to examine the tool's reliability (internal consistency, test-retest reliability) and validity (construct validity, concurrent validity, and known-group validity).\n\nAim: The findings will support the tool's application for early cognitive impairment identification in clinical and research settings.",[28,71,30],[28,346,347,348,29,349,43,350],"MoCA","MoCA-MIS","Validation","screening","memory testing","2025-12-09",{"date":353,"type":48},"2025-12-22",{"date":355,"type":22},"2026-01-01",{"date":179,"type":22},{"name":358,"class":54},"Aristotle University Of Thessaloniki",{"id":360,"slug":361,"hasResults":11,"nctId":362,"briefTitle":363,"officialTitle":363,"acronym":364,"eligibilityCriteria":365,"healthyVolunteers":11,"sex":17,"minAge":366,"maxAge":4,"enrollmentInfo":367,"targetDuration":4,"studyType":299,"phases":4,"briefSummary":369,"conditions":370,"keywords":375,"overallStatus":44,"whyStopped":4,"lastUpdateSubmitDate":382,"lastUpdatePostDateStruct":383,"startDateStruct":385,"completionDateStruct":387,"leadSponsor":389,"locationsCount":55},"100611017","omics-sciences-for-the-identification-of-pathogenetic-mechanisms-and-biomarkers-in-neurodegenerative-diseases-100611017","NCT07235111","Omics Sciences for the Identification of Pathogenetic Mechanisms and Biomarkers in Neurodegenerative Diseases","NeurOmics","Inclusion Criteria\n\n• Patients suffering from neurodegenerative diseases\n\nExclusion Criteria\n\n• Patients not suffering from neurodegenerative diseases","18 Years",{"count":368,"type":22},1200,"The study aims to use 'omics' sciences, employing the most advanced technologies currently available, in order to identify pathogenic genomic variants, proteins and\u002For altered molecular pathways in neurodegenerative diseases and to obtain a new and more complete characterisation of subjects affected by the neurodegenerative diseases under study. Thanks to the integration of genomic, gene expression (transcriptomic and epigenomic), protein and metabolic data and clinical data, the study also aims to identify new markers for the diagnosis, prognosis, also in terms of response to therapy, and monitoring of neurodegenerative diseases.\n\nThe study involves the enrolment of at least 1.200 individuals with neurodegenerative disease.",[325,371,372,28,373,374],"FTD","Young-onset Dementia","Parkinson Disease","ALS (Amyotrophic Lateral Sclerosis)",[376,377,378,379,380,381],"LEWY BODIES DISEASE","young-onset dementia","alzheimer","parkinson","als","mci","2025-11-20",{"date":384,"type":48},"2025-11-25",{"date":386,"type":48},"2025-02-28",{"date":388,"type":22},"2039-09-17",{"name":390,"class":54},"Ospedale Policlinico San Martino",{"id":392,"slug":393,"hasResults":11,"nctId":394,"briefTitle":395,"officialTitle":396,"acronym":397,"eligibilityCriteria":398,"healthyVolunteers":64,"sex":17,"minAge":366,"maxAge":160,"enrollmentInfo":399,"targetDuration":4,"studyType":23,"phases":401,"briefSummary":402,"conditions":403,"keywords":404,"overallStatus":44,"whyStopped":4,"lastUpdateSubmitDate":408,"lastUpdatePostDateStruct":409,"startDateStruct":411,"completionDateStruct":413,"leadSponsor":415,"locationsCount":55},"100474635","neuromodulation-of-memory-in-aging-100474635","NCT05460468","Neuromodulation of Memory in Aging","Adaptive Neuromodulation of Working Memory Networks in Aging and Dementia","TMS-AD","Inclusion Criteria:\n\n* English Speaking\n* Willing to provide consent\n\nExclusion Criteria:\n\n* History of any Axis I DSM-V disorder, excluding major depressive disorder or generalized anxiety disorders\n* Current history of substance abuse or dependence (excluding nicotine)\n* Intracranial implants (e.g. aneurysms clips, shunts, stimulators, cochlear implants, or electrodes), cardiac pacemakers, or vagus Nerve stimulation device\n* Increased risk of seizure for any reason, including prior diagnosis of epilepsy, seizure disorder, increased intracranial pressure, or history of significant head trauma with loss of consciousness for ≥ 5 minutes.\n* Neurological disorder including, but not limited to: space occupying brain lesion; any history of seizures, history of cerebrovascular accident; fainting, cerebral aneurysm, Dementia, Hungtington chorea; Multiple Sclerosis.\n* Current use of medications known to lower the seizure threshold and\u002For affect working memory",{"count":400,"type":22},150,[25],"The proposed research will use closed-loop transcranial magnetic stimulation (TMS) based on individualized brain networks to establish parameters that can reliably control brain states. This will be tested in healthy aging and mild cognitive impairment (MCI) cohorts. The investigators will study network activation and neural oscillatory mechanisms underlying the network that regulates working memory and then target this network using closed-loop TMS to the Prefrontal Cortex. Investigators will measure the impact of TMS on working memory performance and task-based neural activity. The project will use brain stimulation and network modeling techniques to enhance working memory in healthy older adults and MCI and will demonstrate the value of closed-loop, network-guided TMS for future clinical applications.",[29,28],[405,406,407],"TMS","Transcranial Magnetic Stimulation","Memory","2025-10-09",{"date":410,"type":48},"2025-10-14",{"date":412,"type":48},"2024-03-28",{"date":414,"type":22},"2027-06-30",{"name":416,"class":54},"Duke University",{"id":418,"slug":419,"hasResults":11,"nctId":420,"briefTitle":421,"officialTitle":421,"acronym":4,"eligibilityCriteria":422,"healthyVolunteers":64,"sex":17,"minAge":366,"maxAge":215,"enrollmentInfo":423,"targetDuration":4,"studyType":23,"phases":425,"briefSummary":426,"conditions":427,"keywords":433,"overallStatus":44,"whyStopped":4,"lastUpdateSubmitDate":437,"lastUpdatePostDateStruct":438,"startDateStruct":440,"completionDateStruct":442,"leadSponsor":444,"locationsCount":55},"100592899","phase-1-exploring-the-utility-of-18f3f4ap-for-demyelination-imaging-100592899","NCT06999434","Exploring the Utility of [18F]3F4AP for Demyelination Imaging","Inclusion:\n\n1. Male and Female subjects must be ≥18 and \\\u003C90 years of age;\n2. Able to understand and provide informed consent prior to study procedures\n3. Must be in good health\n\nExclusion:\n\n1. Less than 18 years of age;\n2. Pregnant or breastfeeding;\n3. Any significant systemic illness or unstable medical condition;\n4. Pre-existing medical conditions or claustrophobic reactions;\n5. Research-related radiation exposure exceeds current PET Center guidelines (i.e. 50 mSv in the prior 12 months);\n6. History of a bleeding disorder or are currently taking anticoagulants.",{"count":424,"type":22},105,[104],"The overall objective is to obtain an assessment of the pharmacokinetics of \\[18F\\]3F4AP in healthy volunteers and subjects with demyelinating diseases such as mild cognitive impairment (MCI), Alzheimer's Disease (AD), Multiple Sclerosis (MS), Spinal Cord Injury (SCI) and Spinal radiculopathy (SR).",[428,28,429,430,431,432],"Demyelinating Disorders","Alzheimer's Disease (AD)","MS (Multiple Sclerosis)","SCI - Spinal Cord Injury","Spinal Radiculopathy",[434,428,435,436,114],"3F4AP","MS","SCI","2025-05-22",{"date":439,"type":48},"2025-05-31",{"date":441,"type":48},"2025-05-05",{"date":443,"type":22},"2030-05-05",{"name":445,"class":54},"Yale University",{"id":447,"slug":448,"hasResults":11,"nctId":449,"briefTitle":450,"officialTitle":451,"acronym":4,"eligibilityCriteria":452,"healthyVolunteers":64,"sex":17,"minAge":159,"maxAge":215,"enrollmentInfo":453,"targetDuration":4,"studyType":23,"phases":455,"briefSummary":456,"conditions":457,"keywords":4,"overallStatus":44,"whyStopped":4,"lastUpdateSubmitDate":460,"lastUpdatePostDateStruct":461,"startDateStruct":463,"completionDateStruct":465,"leadSponsor":467,"locationsCount":55},"100581460","phase-2-efficacy-and-safety-of-dimethyl-fumarate-among-patients-with-mild-cognitive-impairment-and-dementia-due-to-alzheimers-disease-100581460","NCT06850597","Efficacy and Safety of Dimethyl Fumarate Among Patients with Mild Cognitive Impairment and Dementia Due to Alzheimer's Disease","Randomized, Double-blind, Placebo- Controlled Trial Evaluating Efficacy and Safety of Dimethyl Fumarate in Brain Atrophy Reduction, Synaptic Functional Connectivity, Cognitive Functions, Quality of Life, and Activity of Daily Living Improvement Among Patients with Mild Cognitive Impairment and Dementia Due to Alzheimer's Disease","Inclusion Criteria:\n\n1. Men and women aged 55-90 years.\n2. Patients diagnosed with mild cognitive impairment in Alzheimer's disease and mild to moderate Alzheimer's dementia (MMSE \\>16) diagnosed based on NIA-AA criteria.\n3. MMSE score from 17 to 30 points.\n4. CDR score from 0.5 to 2.\n5. The patient signs an informed, voluntary consent to participate in the study.\n6. The patient has a close person\u002Fde facto guardian who agrees to help the patient during participation in the study.\n7. At least 6 years of education.\n8. In the case of anti-Alzheimer's drugs, the use of cholinesterase inhibitors is permitted provided that they are included at least 3 months before entering the study and used at a stable dose for at least 60 days before entering the study. In the case of memantine, its use is permitted provided that it is included at least 4 months before entering the study and used at a stable dose for at least 3 months before entering the study.\n\nExclusion Criteria:\n\n1. Lack of informed voluntary consent to participate in the study.\n2. Patients who cannot read or write.\n3. Pregnant, breastfeeding or childbearing women who do not use effective contraception (hormonal contraception, surgical sterilization, intrauterine device, condom in combination with vaginal spermicide).\n4. Participation in another clinical trial, currently or within 3 months prior to the screening visit.\n5. Liver failure (i.e. cirrhosis or active liver disease), diagnosed acute or chronic hepatitis regardless of cause.\n6. Chronic kidney disease with GFR below \\\u003C 60 ml\u002Fmin\u002Fm2\n7. Abnormal liver parameters: ALAT exceeding \\> 2 times the upper limit of normal\n8. Leukopenia (\\\u003C4000\u002Fmm3), granulocytopenia (\\\u003C1500\u002Fmm3) or lymphopenia (\\\u003C1000\u002Fmm3) regardless of the cause.\n9. Severe agitation.\n10. Mental retardation.\n11. Delirium diagnosed according to DSM-5 criteria.\n12. Diagnosis of neurological and neurodegenerative diseases other than Alzheimer's disease (multiple sclerosis, Parkinson's disease, Huntington's disease, previous stroke).\n13. Presence of hemorrhagic foci in magnetic resonance imaging with a diameter of ≥ 2 cm3, more than three (3) ischemic stroke foci with a diameter of ≥ 1.5 cm3 or a single ischemic foci with a diameter of ≥ 2 cm3, presence of vascular malformations, aneurysms, subdural hematoma, normal pressure hydrocephalus, final decision at the discretion of the investigator.\n14. Severe or uncontrolled somatic disease that could affect the course of the study (e.g. neoplastic, cardiovascular, respiratory, metabolic or digestive, severe renal failure, unstable type I or II diabetes, untreated or uncontrolled clinically significant hypertension).\n15. Use of benzodiazepines or barbiturates within 1 week prior to screening.\n16. Pharmacological immunosuppression.\n17. Patients with bipolar disorder or psychotic disorders or any other psychiatric condition (current or past) that the Investigator believes interferes with the study.\n18. Alcoholism or drug addiction as defined by DSM-5 within the past 5 years (dependent for more than 1 year and or in remission for less than 3 years).\n19. Patients with any medical condition that, in the Investigator's judgment, is an exclusion criterion.\n20. Thyroid hormone therapy initiated, discontinued, or modified within 3 months prior to screening visit.\n21. Menopausal hormone replacement therapy initiated, discontinued, or modified within 3 months prior to screening visit.\n22. Use of prohibited drugs in the study: Antineoplastic drugs (no studies). Immunosuppressive drugs (no studies). Corticosteroids (impact on project results). Live attenuated vaccines (no studies). Inactivated vaccines may be used. Benzodiazepines (impact on assessed endpoints). Other ethyl esters used orally or topically.",{"count":454,"type":22},30,[194],"The goal of this clinical trial is to assess the degree of improvement in cognitive functions, including memory, attention, thinking, executive and language functions in diagnosed patients MCI and AD taking dimethyl fumarate 480 mg daily compared to patients taking placebo. Participant will be 55 to 90 years old, both genders. The main question it aims to answer is: Changing the degree of cognitive improvement based on the RBANS score among patients diagnosed with MCI and AD after completing dimethyl fumarate therapy test group compared to the placebo group.",[28,458,459],"MCI-AD, Early Stage Alzheimer's Disease","Alzheimer's Disease","2025-02-24",{"date":462,"type":48},"2025-02-27",{"date":464,"type":48},"2024-10-28",{"date":466,"type":22},"2027-12-31",{"name":468,"class":54},"Medical University of Lodz",{"id":470,"slug":471,"hasResults":11,"nctId":472,"briefTitle":473,"officialTitle":473,"acronym":4,"eligibilityCriteria":474,"healthyVolunteers":64,"sex":17,"minAge":18,"maxAge":190,"enrollmentInfo":475,"targetDuration":4,"studyType":23,"phases":477,"briefSummary":478,"conditions":479,"keywords":4,"overallStatus":44,"whyStopped":4,"lastUpdateSubmitDate":482,"lastUpdatePostDateStruct":483,"startDateStruct":485,"completionDateStruct":487,"leadSponsor":489,"locationsCount":55},"100573486","identification-of-neuroinflammation-and-neuroimaging-biomarkers-through-data-driven-artificial-intelligence-techniques-for-unraveling-the-heterogeneity-of-aged-subjects-at-risk-of-dementia-and-to-better-inform-prevention-strategies-100573486","NCT06746909","Identification of Neuroinflammation and Neuroimaging Biomarkers Through Data Driven Artificial Intelligence Techniques for Unraveling the Heterogeneity of Aged Subjects at Risk of Dementia and to Better Inform Prevention Strategies","Inclusion Criteria:\n\n* age between 65 and 89 years; 5 years of schooling;\n* diagnosis of Mild Cognitive Impairment (Croisile et al., 2011) or\n* diagnosis of Subjective Cognitive Decline (Jessen et al., 2014).\n\nExclusion Criteria:\n\n* neurological pathologies; dementia;\n* psychiatric disorders;\n* pathologies or orthopedic problems limiting participation to the aerobic physical training program and to the MR imaging.",{"count":476,"type":22},115,[25],"SCD and MCI are very heterogeneous conditions, which can be prodromal to different types of dementia. The application of data driven clustering methods on neuroimaging and inflammatory data aims at identifying the features characterizing subgroups of subjects at high risk of developing overt dementia. This approach promises to develop tailored early interventions for subjects with profiles of cognitive decline correlating with high risk of progression. To this end in this project, we propose to examine in these subjects both brain structure and cerebral blood flow (CBF) through MR T1-weighted and pCASL (pseudo-continuous arterial spin labeling) imaging and the neuroinflammatory status. The latter will be done by measuring the populations of innate and adaptive immune cells, the chemokines that are required to attract these cells to their potential sites of action in the CNS, and the cytokines by means they exert their function. The analyses performed in aged subjects with MCI and in SCD, will allow identifying common mechanisms predisposing to an increased susceptibility to progression to overt cognitive decline.",[28,480,481],"SCD","Healthy","2024-12-20",{"date":484,"type":48},"2024-12-24",{"date":486,"type":48},"2022-02-01",{"date":488,"type":22},"2026-06-30",{"name":490,"class":54},"IRCCS Fondazione Stella Maris",{"id":492,"slug":493,"hasResults":11,"nctId":494,"briefTitle":495,"officialTitle":495,"acronym":4,"eligibilityCriteria":496,"healthyVolunteers":64,"sex":17,"minAge":132,"maxAge":100,"enrollmentInfo":497,"targetDuration":499,"studyType":299,"phases":4,"briefSummary":500,"conditions":501,"keywords":4,"overallStatus":44,"whyStopped":4,"lastUpdateSubmitDate":504,"lastUpdatePostDateStruct":505,"startDateStruct":506,"completionDateStruct":508,"leadSponsor":510,"locationsCount":55},"100541897","the-effects-of-social-isolation-and-social-interaction-on-the-risk-of-dementia-progression-and-brain-function-in-scd-subjective-cognitive-decline-scd-100541897","NCT06335836","The Effects of Social Isolation and Social Interaction on the Risk of Dementia Progression and Brain Function in SCD (Subjective Cognitive Decline, SCD)","Inclusion Criteria:\n\n* SCD\n\n  1. Self-perceived continuous cognitive decline compared with the previous normal state, and is not related to acute events;\n  2. After adjustment for age, gender, and years of education, the standard cognitive test is normal, or the diagnostic criteria for MCI are not met;\n  3. Selected candidates can sign the informed consent form themselves.\n\nExclusion Criteria:\n\n* (a) Aged under 45 years or older than 85 years; (b) Vascular dementia or other central nervous system diseases; (c) Hachinski Ischemic Scale score \\> 4 points; (d); Unable to complete neuropsychological tests (e.g., blindness, deafness, severe language impairment); (e) Drug abuse or alcohol dependency within the last 6 months; (f) Current participation in other cognition studies; (g) Severe diabetes mellitus, or severe cardiovascular disease, cerebrovascular disease, liver diseases, kidney diseases, psychiatric disorders; (h) Contraindications to imaging techniques: claustrophobia, metallic implants (e.g., intracranial metal clips), electronic devices (e.g., cardiac pacemakers)",{"count":498,"type":22},209,"5 Years","The goal of this clinical trial is to learn about the effects of social isolation and social interaction on the risk of dementia progression and brain function in SCD\n\n1. To explore the association between social isolation and lonely SCD populations and the occurrence and progression of MCI and AD through cross-sectional studies, cohort studies and randomized controlled trials of SCD;\n2. To clarify the correlation between different carrier states, resting brain function connectivity characteristics, and dual-task walking ability of APOEε4 allele and the progression of SCD to MCI and AD during the cognitive progress of people with SCD affected by social isolation;\n3. Establish a predictive model of cognitive decline from SCD to MCI and AD, and apply it to the SCD population to carry out individualized interventions;\n4. Confirm the protective effect of social interaction on cognitive level and brain function in SCD patients.",[502,480,503,28,29,114,325],"Social Isolation","Subjective Cognitive Decline","2024-03-21",{"date":412,"type":48},{"date":507,"type":48},"2024-03-01",{"date":509,"type":22},"2028-12-30",{"name":511,"class":54},"The First Affiliated Hospital with Nanjing Medical University",{"id":513,"slug":514,"hasResults":11,"nctId":515,"briefTitle":516,"officialTitle":517,"acronym":518,"eligibilityCriteria":519,"healthyVolunteers":64,"sex":17,"minAge":99,"maxAge":4,"enrollmentInfo":520,"targetDuration":4,"studyType":23,"phases":522,"briefSummary":523,"conditions":524,"keywords":527,"overallStatus":83,"whyStopped":4,"lastUpdateSubmitDate":538,"lastUpdatePostDateStruct":539,"startDateStruct":541,"completionDateStruct":543,"leadSponsor":544,"locationsCount":55},"100501530","ipaces-v3-mci-nia-protocol-copied-for-ipaces-v4-pd-ninds-100501530","NCT05810454","iPACES v3 MCI NIA Protocol Copied for iPACES v4 PD NINDS","Neuro-exergaming for the Prevention and Remediation of Decline Due to Parkinson's Disease: Clinical Trial of the Interactive Physical and Cognitive Exercise System (iPACES-PD)","iPACES-PD","Inclusion Criteria:\n\n1. 50 years of age or older\n2. meets criteria for MCI (per site staff\u002FMD\u002Fneuropsychologist and confirmed by study-administered Montreal Cognitive Assessment; MoCA; score = between 16-26, non-inclusive; Milani, 2018)\n\n4\\. available for participation for one year (tablet surveys, videoconference evaluations) 5. willing and able to exercise 3-5 times per week for at least 6 months 6. can pedal an under-table elliptical 7. can read off of a small tablet screen 8. proficient in English (speaking and reading for completion of interview, surveys, game); Spanish language option anticipated soon 9. can participate in testing and read and operate tablet touch screen (adequate hearing, vision, speech) 10. written approval from primary care physician and cardiologist (if applicable) to participate in exercise for this study 11. can provide informed consent\n\nExclusion Criteria:\n\n1. already exercising at recommended levels (45 min of moderate intensity aerobic exercise 5-7x\u002Fwk)\n2. significant history of cardiovascular problems\n3. significant history of stroke\n4. significant history of memory problems (e.g., dementia\u002FAlzheimer's)\n5. significant history of other neurological condition (e.g., seizures, etc.)\n6. significant uncontrolled tremor such that would interfere with touch-screen use required throughout the study (surveys, game-play, etc.)\n7. not prone to cybersickness (e.g., \"car sickness\" or problems with \"screen time\")\n8. cannot provide informed consent (i.e., when phone screened with the Impaired Decision Making Capacity screen)",{"count":521,"type":22},120,[25],"The primary purpose of this study is to attempt to replicate and extend promising pilot findings regarding the cognitive benefits of in-home neuro-exergaming with iPACES (interactive Physical and Cognitive Exercise System v3) for persons with mild cognitive impairment (MCI), to evaluate effects for persons with Parkinson's Disease (PD). Participants will include persons with PD, and potentially, also their co-residing partner, who will exercise at home or accessible location, 3-5 times per week for at least 6 months, with follow-up one month after the main intervention. All participation is \"remote\" (completed at home, or location of choice), utilizing either one's own equipment (\"bring-your-own-devices\" BYODs: pedaler, phone\u002Ftablet, smart-watch) or some equipment which may be supplied by the grant-funded study and shipped directly to the home; all study measures are completed remotely (e.g., via phone app, website, biometric device, videoconference, email, snail mail, etc.).",[525,526,29,28],"Parkinson's Disease","PD",[528,529,530,531,532,533,534,535,536,537],"Parkinson","exercise","exergame","physical activity","neuro-exergaming","neuropsychological","cognitive","dual-task","interactive","executive function","2023-04-11",{"date":540,"type":48},"2023-04-12",{"date":542,"type":22},"2023-08",{"date":149,"type":22},{"name":545,"class":125},"iPACES LLC",{"id":547,"slug":548,"hasResults":11,"nctId":549,"briefTitle":550,"officialTitle":551,"acronym":4,"eligibilityCriteria":552,"healthyVolunteers":64,"sex":17,"minAge":99,"maxAge":4,"enrollmentInfo":553,"targetDuration":4,"studyType":299,"phases":4,"briefSummary":555,"conditions":556,"keywords":4,"overallStatus":44,"whyStopped":4,"lastUpdateSubmitDate":559,"lastUpdatePostDateStruct":560,"startDateStruct":562,"completionDateStruct":564,"leadSponsor":566,"locationsCount":55},"100390153","cognitive-impairment-in-ageing-people-100390153","NCT04360200","Cognitive Impairment in Ageing People","Cognitive Impairment in Ageing People: A Longitudinal Observational Prospective Study","Inclusion Criteria:\n\n1. Patients over 50 years old.\n2. Sign informed consent.\n3. According to DSM-IV, the diagnostic standard of dementia was not met.\n4. The clinical dementia rating (CDR) was 0.5.\n\nExclusion criteria:\n\n1. Subjects with mental retardation.\n2. Refuse to have blood sampling, imaging and other examinations.\n3. Uncooperative subjects that have serious organic diseases, or have a history of mental illness, or have physical disability (including severe aphasia).\n4. Contraindications of MR scanning.\n5. Suffering from serious physical or mental illness.",{"count":554,"type":22},5000,"Mild cognitive impairment (MCI) and neurocognitive disorder such as Alzheimer's disease (AD) and Vascular dementia (VaD) have become common diseases in the elderly. The burden of dementia is rising in China, with major medical, social and economic impacts. To address this important public health problem, cohort study on elderly cognitive disorders should be carry out. The methods of early prevention, early diagnosis and early treatment the cognitive disorders in elderly should be found to reduce the burden of the social and economic issue due to dementia. At present, the international corresponding guidelines have taken gene and brain imaging biomarkers as important indicators of dementia pathogenesis research, accurate diagnosis and targeted intervention. The study will construct a prospective cohort to establish database that provide not only comprehensive epidemiological data on the MCI and neurocognitive disorder in ageing people, but also complete the construction of biological samples bank and clinical diagnosis and treatment information database. Using the database, the study will identify the conversion rates from MCI to dementia and risk factors for the progression from MCI to dementia or AD. The study will also apply and develop brain structural and pathological imaging technology to support precision diagnosis of senile cognitive disorders. The study have goals to identify and validate imaging and blood\u002FCSF biomarkers for the early detection and tracking of cognitive disorders.",[28,325,557,558],"VAD - Vascular Dementia","Cognitive Impairment","2020-09-11",{"date":561,"type":48},"2020-09-14",{"date":563,"type":48},"2020-04-01",{"date":565,"type":22},"2040-12",{"name":567,"class":54},"Yamei Tang"]